Background. The recently introduced CKD-EPI creat-cys equation surpassed creatinine-based equations for GFR estimation in a large cross-sectional analysis. However, its performance to predict individual risk of CKD progression and death in patients with various underlying CKD etiologies is unknown. Methods. We recruited 444 patients with CKD GFR categories 2-4 (eGFR 15-89 mL/min/1.73 m
I N T RO D U C T I O N
Correct assessment of renal function is of paramount importance for guidance of therapy and decision-making in patients with chronic kidney disease (CKD). Numerous large-scale epidemiological studies found glomerular filtration rate (GFR) and albuminuria to be by far the best predictors of progression of renal disease [1, 2] . As a direct measurement of glomerular filtration rate (mGFR) is cumbersome, a rapid and accurate estimate of GFR (eGFR) that is predictive of renal outcomes is required.
In recent years, new estimation formulas have been introduced [3, 4] . In the last decade, the MDRD equation to estimate eGFR has largely replaced the Cockroft-Gault equation to estimate creatinine clearance in clinical practice [5] . More recently, the creatinine-based CKD-EPI formula (CKD-EPI creat ) was shown to more accurately estimate GFR than MDRD [3] ; in a meta-analysis, CKD-EPI creat better categorized mortality and end-stage renal disease risk compared with the MDRD equation [6] . Very recently, a large-scale cross-sectional analysis established a novel cystatin C-and creatininebased CKD-EPI equation (CKD-EPI creat-cys ) that estimated mGFR even better than the original creatinine-based CKD-EPI creat equation [4] . However, the introduction of ever novel equations in very short intervals may cause confusion outside the nephrology community, which may hamper rather than encourage the routine use of these equations in general medicine [7] . Therefore, it is mandatory to demonstrate that these novel equations bear meaningful clinical advances beyond more accurate GFR estimation, such as better prediction of CKD progression and death. This would allow a more tailored allocation of high-risk patients to renoprotective intervention.
The 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease recommended staging to be based on both an eGFR and albuminuria and introduced a graded risk category according to the combination of eGFR and albuminuria CKD categories [8] . Nonetheless, the prognostic implications of stratifying patients by CKD-EPI creat-cys , and of combining CKD-EPI creat or CKD-EPI creat-cys eGFR categories with albuminuria categories, has not yet been investigated among CKD patients with a broad spectrum of underlying etiologies.
Our ongoing CARE FOR HOMe study, which recruits patients referred to a tertiary nephrology centre for outpatient care, allows comparison of the well-established MDRD and CKD-EPI creat equations with the novel CKD-EPI creat-cys equation as predictors of CKD progression and death.
S U B J E C T S A N D M E T H O D S
In the ongoing CARE FOR HOMe study, clinically stable CKD patients from the outpatient department of a tertiary referral centre are recruited. The CARE FOR HOMe study, which aims to identify novel predictors of cardiovascular and renal outcome in CKD [9, 10] , was approved by the local Ethics Committee, and all patients provided written informed consent. The study was performed in accordance with the Declaration of Helsinki.
Inclusion criteria were the presence of CKD with GFR categories 2-4 (eGFR between 15 and 89 mL/min/1.73 m 2 , as estimated by MDRD equation 4).
We excluded allograft recipients, pregnant women, patients <18 years of age, patients under systemic immunosuppressive medication, patients with human immunodeficiency virus infection, with clinically apparent infections (defined as C-reactive protein levels >50 mg/L, and/or requiring systemic antibiotic therapy), with active malignancy or with acute kidney injury (defined as increase of plasma creatinine >50% within the preceding 4 weeks).
History of smoking, diabetes mellitus, current drug intake and cardiovascular comorbidity was recorded by a standardized questionnaire. Reported comorbidity was verified by chart review.
Prevalent cardiovascular disease was defined as a history of myocardial infarction, coronary artery angioplasty/stenting/ bypass surgery, major stroke, carotid endarterectomy/stenting, nontraumatic lower extremity amputation or lower limb artery angioplasty/stenting/bypass surgery.
Patients were categorized as active smokers if they were current smokers or had stopped smoking <1 month before entry into the study. Patients with self-reported or physicianreported diabetes mellitus, with a fasting blood glucose level of >126 mg/dL or with current use of hypoglycemic medication, were categorized as diabetic.
Each patient was placed into a GFR category based on each eGFR estimating equation, MDRD, CKD-EPI creat and CKD-EPI creat-cys . Similarly, each patient was allocated a CKD risk category for each combination of GFR categories allocated by each estimating equation, and albuminuria categories. Definition of GFR categories (G1: ≥ 90; G2: 60-89; G3a: 45-59; G3b: 30-44; G4: 15-29; G5: <15 mL/min/1.73 m 2 ), albuminuria categories (A1: <30; A2 30-300; A3 >300 mg/g creatinine) and CKD risk categories (low, medium, high and very high) were in accordance with 2012 KDIGO guidelines [8] .
Laboratory measurements
We obtained blood samples after an overnight fast for measuring plasma creatinine and cystatin C. Plasma creatinine was traceable to IDMS, cystatin C was analyzed via turbidometric assay (Roche, Mannheim, Germany).
Albuminuria was quantified as the albumin-creatinine-ratio. In eight patients, no data on albuminuria were available from the baseline visit; in these patients, we referred to albuminuria data from the preceding visit to our outpatient department. In one single patient who had undergone ureterosigmoidostomy, no urinalysis could be performed.
Endpoint
All patients were invited annually for follow-up examinations. Patients who did not attend annual follow-up visits were contacted via telephone, and information on laboratory values was obtained from their general primary-care physician.
The combined endpoint (the event) was death, need for renal replacement therapy (RRT) or halving of eGFR, whichever occurred first. Intermittent need for RRT or transient decline of eGFR with subsequent renal function recovery was not considered an event. A specialist in nephrology confirmed all clinical events by review of medical charts. All patients were followed up until 31 May 2013.
Statistical analysis
Categorical variables are presented as a percentage of patients and compared using the Chi-square test. Continuous data are expressed as means ± standard deviation, and were compared using a t-test for two independent samples. Albuminuria, CRP and parathyroid hormone are presented as median (inter-quartile range) because of skewed distribution, and compared by the Mann-Whitney U test.
Reclassification analysis. To assess the comparative ability of each estimating equation to classify patients to GFR categories that most appropriately reflected risk of the endpoint (the event), we used classification tables. Two classification tables were constructed to assess the difference between MDRD and CKD-EPI creat-cys and two to assess the difference between CKD-EPI creat and CKD-EPI creat-cys . Two tables, one for patients who went on to have the event and one for patients who did not go on to have the event, enable analysis of both the comparative ability of the classification schemes to reflect risk of an event and risk of no-event. The statistical metric used in each case is the net reclassification improvement (NRI) [11] .
The difference between the proportion of patients experiencing an event who moved to a lower GFR (or higher CKD risk) category, and the proportion of patients experiencing an event who moved to a higher GFR (or lower CKD risk) category, was defined as NRI events [11] . Similarly, the difference between the proportion of patients without an event who moved to a higher GFR category (or lower CKD risk) and the proportion of patients without an event who moved to a lower GFR (or higher CKD risk) was defined as NRI non-events . 95% confidence intervals for NRI events and NRI non-events were calculated using a bootstrap method [12] .
NRI events and NRI non-events were calculated for the reclassification to different GFR categories and CKD risk categories by CKD-EPI creat-cys eGFR compared with MDRD eGFR and CKD-EPI creat eGFR.
Added value of albuminuria. To analyze the prognostic implications of adding albuminuria to GFR estimates, we compared two logistic regression models, the reference model comprising only eGFR estimated by each estimating equation and the new model comprising eGFR and log-transformed albuminuria. Each model enables the calculation of a risk ( probability) of the endpoint outcome (the event) for every patient. These risks are then used to calculate the area under the receiver operator characteristic curves (AUC) for each model which are then compared using the method of DeLong [13] . More powerful analytical techniques than the AUCs are the risk assessment plots (RAP) as published recently [12] along with the associated metrics, the integrated discrimination improvement (IDI), category-free NRI (cfNRI), integrated sensitivity (IS) and integrated 1-specificity (IP) [14] . The RAP is the plot, for each of the reference and the new (with albuminuria) models, of risk verse sensitivity for patients with the event and risk verse 1-specificity for patients without the event. The metrics are more meaningful than the AUC, because they do not simply reflect a comparative ranking of risks, but use the actual calculated value and because, unlike the AUC, the IDI and cfNRI may be calculated separately for those with the event and for those without. The cfNRI events and cfNRI nonevents reflect the net proportion of patients with the event with increased risk or without the event with decreased risk after the addition of albuminuria to the reference model. The IDI events and IDI non-events reflect the extent of change in risk, not merely the direction of change as with cfNRIs. The IDI events is the difference in mean risk (of those with events) in the reference model and mean risk in the new model (i.e. with the addition of albuminuria). Similarly, the IDI non-events is the difference between mean risks of the two models for those without the event. cfNRI events , cfNRI non-events , IDI events and IDI non-events are all positive when the addition of albuminuria to the estimating GFR equation more appropriately risk stratifies the cohort (i.e. those with the event have net higher risks, those without the event net lower risks). The IS, ideally one, and IP, ideally zero, for each model represent how good the model is at allocating high risk to those with the event and low risk to those without. These metrics and their use have recently been discussed in depth by Pickering and Endre [12] .
Matlab 2012b (MathWorks, Natick, MA, USA) was used for statistical analyses.
R E S U LT S

Baseline characteristics
All CARE FOR HOMe participants had baseline measurements of plasma creatinine and cystatin C, and a follow-up period of at least 6 months after initial recruitment (n = 444). Baseline eGFR was 45.2 ± 15.9, 47.0 ± 18.0 and 45.2 ± 18.4 mL/min/1.73 m 2 according to MDRD, CKD-EPI creat and CKD-EPI creat-cys equations, respectively. Further baseline characteristics are summarized in Table 1. A total of 87, 147, 123 and 87 were in GFR categories G2, G3a, G3b and G4 according to the MDRD equation; CKD-EPI creat-cys reclassified 73 (16.4%) patients to more advanced GFR categories and 44 (9.9%) patients to less advanced GFR categories, 327 (73.6%) patients remained in the same GFR categories ( Table 2) .
According to the CKD-EPI creat equation, 1, 112, 128, 112, 89 and 2 patients were in GFR categories G1, G2, G3a, G3b, G4 and G5, respectively; CKD-EPI creat-cys reclassified 84 (18.9%) patients to more advanced GFR categories and 27 (6.1%) patients to less advanced GFR categories (Table 2) .
A Bland-Altman plot of the average of the two estimating equations plotted against their difference showed CKD-EPI creat-cys and MDRD to be similar at lower eGFR, and CKD-EPI creat-cys to be greater than MDRD at higher eGFR ( Figure 1A ). There was no bias comparing CKD-EPI creat-cys and CKD-EPI creat ( Figure 1B ).
Outcomes
At study end in May 2013, renal outcome and vital status were known in all patients. During a follow-up of 2.7 ± 1.2 years, 62 patients suffered the predefined endpoint, of whom 35 required chronic renal-replacement therapy, six had a halving of eGFR without subsequent initiation of RRT, and 21 died without prior halving of eGFR and/or need for RRT.
As expected, patients who reached the predefined endpoint had higher albuminuria, higher plasma phosphate, higher parathyroid hormone and lower eGFR at baseline, while they did not differ in age, smoking status and prevalence of diabetes mellitus and prevalence of cardiovascular disease ( Table 1) .
The numbers of patients reaching the predefined endpoint across GFR categories are given in Table 2 . Among the 62 patients who suffered an event, 18 were reclassified from MDRD GFR categories to a more advanced GFR category by CKD-EPI creat-cys , and one patient moved to a less advanced GFR category, yielding an NRI event of 27.4% (CI: 16.7-40.0%). Of the 382 patients who did not experience an event, 55 patients moved to a higher GFR category by CKD-EPI creat-cys , and 43 moved to a lower GFR category, resulting in a NRI non-events of −3.1% (CI: −8.2 to 1.6%).
Similarly, among the 62 patients who suffered an event, 16 were reclassified from CKD-EPI creat GFR categories to a more advanced GFR category by CKD-EPI creat-cys and two patients moved to a less advanced GFR category, yielding an NRI event of 22.6% (CI: 10.2 to 34.3%). Of the 382 patients who did not experience an event, 68 patients moved to a higher GFR category, and 25 moved to a lower GFR category, resulting in a NRI non-events of −11.3% (CI: −15.9 to −6.5%).
Addition of albuminuria
The AUC for eGFR equations with and without the addition of albuminuria was good (∼0.8). The addition of albuminuria, though, to each of the eGFR equations increased the AUCs only marginally from ∼0.79 to 0.82 and with Pvalues of 0.09-0.16, suggesting the observed increase in AUC may have occurred by chance. However, the calculated risk of the endpoint event increased for a net 26-32% in those of who went on to have the event (cfNRI event ), and reduced the calculated risk in a net 21-23% in those of whom did not have the event (cfNRI non-event ; Table 3 ). The extent of the change in risk, though, was minimal for those who did not have the event. That is the decrease in average risk, IDI non-event , was ≤0.005 in all cases. For those who did have the event, there was a small, but potentially clinically meaningful, increase in risk, an IDI event of 0.027-0.033 (Table 3) . Similarly, all models ascribed a low calculated risk to those who did not have the event (IP∼0.1). Conversely, the models were poor at ascribing a high risk to those who went on to have the event (IS ≤ 0.3). The risk assessment plots indicated that the addition of albuminuria made the greatest increase in calculated risk in those with a calculated risk of >0.4 by the model with the eGFR equation alone (Figure 2 ).
CKD risk categories including albuminuria
When integrating categories of eGFR and of albuminuria into CKD risk categories, patients with 'low' and 'medium' CKD risk categories, both had very low risk for suffering an event (Tables 4 and 5 ). Irrespective of the method of 
O R I G I N A L A R T I C L E
C K D -E P I c r e a t -c y s e q u a t i o n a n d r i s k p r e d i c t i o n estimating eGFR the 'high' risk category conferred a 7-9% risk (7/101 MDRD, 8/97 CKD-EPI creat and 8/93 CKD-EPI creat-cys ), and the 'very high' category an ∼28% risk (50/178 MDRD, 49/ 173 CKD-EPI creat and 51/186 CKD-EPI creat-cys ). There was no net difference in allocation to risk categories when using eGFR by CKD-EPI creat-cys compared with MDRD [NRI event was 4.9% (−1.5 to 14%), NRI non-event was −0.26% (−4.3 to 4.9%)]. There was possible improved allocation to risk categories when using eGFR by CKD-EPI creat-cys compared with CKD-EPI creat for those with events [NRI event was 6.6% (0-16%)], but worse net difference in allocation for those without events [NRI non-event was −7.3% (−11.4 to −0.3.2%)].
D I S C U S S I O N
We compared the predictive performance of the recently introduced CKD-EPI creat-cys equation and the established MDRD and CKD-EPI creat equations in our CARE FOR HOMe study, a well-characterized cohort representing a broad CKD spectrum. Of all equations, the CKD-EPI creat-cys equation allowed best prediction of CKD progression and death. This is because compared with the MDRD or CKD-EPI creat , CKD-EPI creat-cys classified more of the patients who went on to have an outcome event to more advanced GFR categories.
Our findings supplement the recent cross-sectional analysis from the Chronic Kidney Disease Epidemiology Collaboration, where CKD-EPI creat-cys better estimated glomerular filtration rate than equations based only on creatinine [4] . We now provide evidence that reclassification of CKD patients from MDRD or CKD-EPI creat determined GFR categories to CKD-EPI creat-cys determined GFR categories has clinical consequences. On the one hand, reclassification to more advanced GFR categories was associated with worse outcome, thus identifying additional patients who are in need of closer follow-up and more aggressive treatment. On the other hand, reclassification to less advanced GFR categories could impact healthcare systems, leading to cost savings; e.g. moving a nonalbuminuric patient from GFR category 4 to category 3b would obviate the need for his referral to a nephrologist according to recent KDIGO guidelines [8] . Compared with MDRD, there was no net reclassification to less advanced GFR categories by CKD-EPI creat-cys among those who did not have an endpoint event. However, compared with CKD-EPI creat there was a net increase in the proportion of patients reclassified to more advanced GFR categories by CKD-EPI creat-cys among those who did not have an endpoint event (NRI non-events : −11.3%). Similar to making trade-offs between sensitivity and specificity when determining appropriate thresholds for diagnosis using biomarkers, there is a trade-off in using CKD-EPI creat-cys . If the most importance is placed on correct categorical allocation to those most likely to progress to the endpoint, then CKD-EPI creat-cys is appropriate (at the expense of increased false positives), on the other hand if the most importance is on allocation of those not-likely to progress, then CKD-EPI creat is appropriate (at the expense of increased false negatives).
We have presented an evaluation of CKD-EPI creat-cys but not CKD-EPI cys because the KDIGO guidelines suggest the use of one or the other and not one in particular. Furthermore, we found no net difference in reclassification between the two cystatin C equations. We present these results and comparisons of the creatinine-based eGFR equations with CKD-EPI cys in a supplement.
Our findings are in partial discrepancy with recent data from Skupien et al., who found the CKD-EPI cys better predicted end-stage renal failure and overall mortality than the CKD-EPI creat-cys equation [15] . Of note, these findings were in a selected cohort of diabetics, most of whom had mild (if any) chronic kidney disease at baseline (median eGFR of the three cohorts studied ranged from 75 to 97 mL/min/1.73 m 2 compared with 46 mL/min/1.73 m 2 in our cohort). In contrast, CARE FOR HOMe recruited patients with diverse underlying etiologies and more advanced CKD at baseline. Therefore, an early rise of cystatin C with incipient CKD, and the interplay of non-GFR determinants of cystatin C (e. g. obesity) may explain these discrepant findings. Future multicenter studies should test the hypotheses that CKD-EPI cys performs better than CKD-EPI creat-cys in early stages of CKD, and that CKD-EPI creat-cys performs better than CKD-EPI cys in more advanced CKD.
Furthermore, as prognostic implications were found across the broad spectrum of CKD in CARE FOR HOMe, our findings partly challenge recent KDIGO recommendations, which advocate use of CKD-EPI creat-cys only in patients in G3a GFR category (45-59 mL/min/1.73 m 2 ) for confirmation following the use of creatinine-based GFR estimation, or in specific conditions when creatinine-based GFR estimation is considered 'less accurate' [8] .
Adding albuminuria to eGFR marginally improved risk prediction in those who went on to have the event than eGFR alone for each of the eGFR equations, which underlines recent KDIGO recommendations. Interestingly, however, the prognostic benefit of using the CKD-EPI creat-cys compared with MDRD is attenuated after consideration of albuminuria, and for CKD-EPI creat-cys compared with CKD-EPI creat was improved for those with events, but worse for those without. We cannot provide a compelling explanation for this finding, and F I G U R E 2 : Risk assessment plots (RAP) illustrating the prognostic gain obtained by adding albuminuria to GFR for predicting the predefined endpoint. RAP was drawn based on event probabilities calculated for each patient from two logistic regression models [reference model: eGFR estimated by (A) MDRD, (B) CKD-EPI creat , (C) CKD-EPI creat-cys ; second model: reference model plus log-transformed albuminuria]. In all cases, the separation between the two event curves is only at a calculated risk >0.4. There is no separation between the two non-event curves [12] . cannot rule out a play of chance. Future cohort studies should re-analyze this issue.
Of note, use of CKD-EPI creat-cys would immensely increase the analytical costs as cystatin C costs are several times that of creatinine. Furthermore, widespread determination of cystatin C has not yet been introduced into clinical routine. Further cost-benefit studies are needed.
Our study has some limitations: patients have been recruited in the state of Saarland, where most inhabitants are Caucasians. This homogeneity in our population in part may explain why when we compared the AUCs of each of the estimating equations with the AUCs for creatinine and cystatin C themselves there was no statistical difference between AUCs. Thus, our study requires confirmation in non-Caucasian populations. Secondly, we did not perform direct measurement of GFR, and thus cannot discern whether superiority of CKD-EPI creat-cys results from a closer association with GFR, as suggested by cross-sectional data from the Chronic Kidney Disease Epidemiology Collaboration, or by non-GFR determinants of cystatin, such as overweight, nicotine abuse and inflammation [16] , which may affect both GFR estimation and patient outcome.
Moreover, our study should not be taken as a validation of CKD-EPI creat-cys as an estimating equation for measured GFR because it does not follow that a good estimating equation is also a good predictor of adverse events [17] . This is probably because non-GFR-determinants like age critically affect eGFR, and therefore may lead to overestimation of CKD prevalence and of CKD-related adverse outcome [17] . In our cohort, a logistic regression model of age, sex, ethnicity, creatinine and cystatin C to predict the combined outcome resulted in only creatinine and cystatin C being independent predictors (P < 0.05) suggesting age was not a dominant factor in this cohort.
Moreover, cystatin C could not be calibrated to reference material since our study was initiated in 2008, before the release of reference material by the Institute for Reference Materials and Measurements in June 2010.
Finally, we report on a medium-sized, single center CKD cohort, and we thus hope that our findings may stimulate others to test our conclusions in larger (multi-center) cohorts.
Our study has several strengths: first, the cohort is contemporary, and patient treatment was in line with European Best Practice Guidelines and KDIGO recommendations. Overall, renal risk factors were under adequate control, as reflected by the baseline blood pressure measurements, albuminuria and phosphate levels. The patients recruited had a broad spectrum of primary kidney diseases, allowing the transfer of our results to the general CKD population. Finally, follow-up was complete.
In conclusion, we demonstrate that application of CKD-EPI creat-cys, compared with the MDRD and CKD-EPI creat equations, allows better prediction of CKD progression and death among CKD patients. Thus, a broader integration of CKD-EPI creat-cys appears attractive for characterization of patients at higher renal risk, who may benefit from intensified nephrological care. . A1, <30 mg/g creatinine; A2, 30-300 mg/g creatinine; A3, >300 mg/g creatinine. n. a., not applicable. Risk categories: low, green; medium, yellow; high, pink; very high, red. Number of patients with and without the outcome event in each risk category (allocated by eGFR and by albuminuria categories).
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